IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
The equity awards were granted to four newly hired employees as an inducement to enter employment with IDEAYA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) granted stock options covering 99,600 shares to newly hired employees on October 29, 2026.
The awards were made under its 2023 Employment Inducement Incentive Award Plan. The exercise price is $32.89 per share, equal to the grant-date closing stock price. The options have a 10-year term and vest over four years, subject to continued service on each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 99,600 shares at a $32.89 exercise price create potential dilution if exercised.
Key Figures
- Options granted
- 99,600 options
- Granted to four newly hired employees
- Exercise price
- $32.89 per share
- Equal to the closing price on the grant date
- Option term
- 10 years
- Term of the stock options
- Vesting period
- 4 years
- Vesting is subject to continued employee service
- Vesting schedule
- 25% / 75%
- 25% at the first anniversary; remaining 75% in equal monthly installments over the following three years
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302924462.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did IDEAYA grant, and what is the exercise price?
IDEAYA granted options to purchase an aggregate of 99,600 common shares to four newly hired employees on October 29, 2026. The exercise price is $32.89 per share, equal to the stock's closing price on the grant date.
What is the vesting schedule for IDEAYA's October 2026 inducement options?
25% of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% vest in equal monthly installments over the following three years. Each vesting date requires the employee's continued service to IDEAYA.